UPCC 12119: An Exploratory Biomarker Study of Metastatic Triple-Negative Breast Cancer Patients Treated with Immune Checkpoint Inhibitors
Enrolling By Invitation
18 years - 99 years
All
Phase
N/A
10 participants needed
1 Location
Brief description of study
The purpose of this research is to collect clinical information and research tissue samples (blood,
tissue, and stool) from patients receiving standard treatment for metastatic triple-negative breast
cancer to help researchers better understand the use of immunotherapy in breast cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Breast Cancer,Breast Cancer
-
Age: 18 years - 99 years
-
Gender: All
18 years of age Breast Cancer
Updated on
04 Aug 2024.
Study ID: 834775
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
